A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00058526
Recruitment Status : Completed
First Posted : April 9, 2003
Last Update Posted : May 15, 2017
Information provided by (Responsible Party):